Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1

Immunology Letters

Volumn 143, Issue 2, 2012, Pages 146-151

  Peng, Wei ^a,b  

^a Shanghai XuHui Centre Hospital   (China)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Anti GM1 antibodies; Cholera toxin; Galectin 1; Intravenous immunoglobulin

Indexed keywords

CELL RECEPTOR; CHOLERA TOXIN; ENDOGLOBULINE; GALECTIN 1; GANGLIOSIDE GM1; GANGLIOSIDE GM1 ANTIBODY; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROPHAGE RECEPTOR; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MACROPHAGE FUNCTION; MOTOR NEUROPATHY; NEUROPATHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; TREATMENT RESPONSE;

AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CELL LINE; CELL MEMBRANE; CHOLERA TOXIN; G(M1) GANGLIOSIDE; GALECTIN 1; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PROTEIN BINDING; TREATMENT OUTCOME;

EID: 84859099858     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.01.005     Document Type: Article

References (52)

1. Azulay J.P., Blin O., Pouget J., Boucraut J., Bille-Turc F., Carles G., et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies. Neurology 1994, 44:429-432.
2. van der Meché F.G., van Doorn P.A., Jacobs B.C. Inflammatory neuropathies-pathogenesis and the role of intravenous immune globulin. J Clin Immunol 1995, 15:63S-69S.
3. Oczko-Walker M., Manousakis G., Wang S., Malter J.S., Waclawik A.J. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis 2010, 12:55-61.
4. Lin C.S., Krishnan A.V., Park S.B., Kiernan M.C. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol 2011, 68:862-869.
5. Soelberg Sorensen P. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Neurodegener Dis 2008, 5:8-15.
6. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001, 345:747-755.
7. Stein M.R. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med 2010, 122:176-184.
8. Nobile-Orazio E. Multifocal motor neuropathy. J Neuroimmunol 2001, 115:4-18.
9. Gong Y., Tagawa Y., Lunn M.P., Laroy W., Heffer-Lauc M., Li C.Y., et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002, 125:2491-2506.
10. Sheikh K.A., Deerinck T.J., Ellisman M.H., Griffin J.W. The distribution of ganglioside-like moieties in peripheral nerves. Brain 1999, 122(Pt 3):449-460.
11. Susuki K., Baba H., Tohyama K., Kanai K., Kuwabara S., Hirata K., et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 2007, 55:746-757.
12. + currents in isolated rat myelinated nerve fibers. Ann Neurol 1995, 37:436-442.
13. Hirota N., Kaji R., Bostock H., Shindo K., Kawasaki T., Mizutani K., et al. The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. Brain 1997, 120(Pt 12):2159-2169.
14. Riggott M.J., Matthew W.D. Anti-idiotypic monoclonal antibodies to GM1 identify ganglioside binding proteins. Glycobiology 1996, 6:581-589.
15. Qi R., Mullen D.G., Baker J.R., Banaszak Holl MM The mechanism of polyplex internalization into cells: testing the GM1/Caveolin-1 lipid raft mediated endocytosis pathway. Mol Pharmaceut 2010, 7:267-279.
16. Kopitz J., von Reitzenstein C., Burchert M., Cantz M., Gabius H.J. Galectin-1 is a major receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. J Biol Chem 1998, 273:11205-11211.
17. Echigo Y., Sugiki H., Koizumi Y., Hikitsuchi S., Inoue H. Activation of RAW264.7 macrophages by oxidized galectin-1. Immunol Lett 2010, 131:19-23.
18. Espelt M.V., Croci D.O., Bacigalupo M.L., Carabias P., Manzi M., Elola M.T., et al. Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization and in vivo tumor growth. Hepatology 2011.
19. Cedeno-Laurent F., Barthel S.R., Opperman M.J., Lee D.M., Clark R.A., Dimitroff C.J. Development of a nascent galectin-1 chimeric molecule for studying the role of leukocyte galectin-1 ligands and immune disease modulation. J Immunol 2010, 185:4659-4672.
20. Cooper D., Ilarregui J.M., Pesoa S.A., Croci D.O., Perretti M., Rabinovich G.A. Multiple functional targets of the immunoregulatory activity of galectin-1: control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol 2010, 480:199-244.
21. Malik U., Oleksowicz L., Latov N., Cardo L.J. Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 1996, 39:136-139.
22. Lopez P.H., Irazoqui F.J., Nores G.A. Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies. J Neuroimmunol 2000, 105:179-183.
23. Piepers S., Jansen M.D., Cats E.A., van Sorge N.M., van den Berg L.H., van der Pol W.L. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol 2010, 229:256-262.
24. Yuki N., Watanabe H., Nakajima T., Spath P.J. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011, 82:87-91.
25. Yuki N., Miyagi F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci 1996, 139:160-162.
26. Azulay J.P., Rihet P., Pouget J., Cador F., Blin O., Boucraut J., et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 1997, 62:391-394.
27. Bartolomei F., Boucraut J., Barrié M., Kok J., Dravet C., Viallat D., et al. Cryptogenic partial epilepsies with anti-GM1 antibodies: a new form of immune-mediated epilepsy?. Epilepsia 1996, 37:922-926.
28. Adams D., Kuntzer T., Burger D., Chofflon M., Magistris M.R., Regli F., et al. Predictive value of anti-GM1 ganglioside antibodies in neuromuscular diseases: a study of 180 sera. J Neuroimmunol 1991, 32:223-230.
29. Mouthon L., Kaveri S.V., Spalter S.H., Lacroix-Desmazes S., Lefranc C., Desai R., et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996, 104(Suppl. 1):3-9. Review.
30. Lehmann H.C., Hartung H.P. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol 2011, 231:61-69.
31. Terryberry J.W., Shoenfeld Y., Sherer Y., Levy Y., Fabrizzi F., Ahmed A., et al. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations. Immunol Invest 2000, 29:337-347.
32. Press R., Mata S., Lolli F., Zhu J., Andersson T., Link H. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barre syndrome. J Neurol Sci 2001, 190:41-47.
33. Masson P.L. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993, 6:683-689.
34. Bleeker W.K., Teeling J.L., Hack C.E. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001, 98:3136-3142.
35. Freiberger T., Grodecka L., Ravcukova B., Kurecova B., Postranecka V., Vlcek J., et al. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency. Clin Immunol 2010, 136:419-425.
36. Krause I., Hacham S., Gilburd B., Damianovitch M., Blank M., Shoenfeld Y. Absence of anti-idiotypic antibodies in IVIG preparations to autoantibodies of rare autoimmune diseases. Clin Immunol Immunopathol 1995, 77:229-235.
37. Yuki N., Yamada M., Koga M., Odaka M., Susuki K., Tagawa Y., et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001, 49:712-720.
38. Shahrizaila N., Yuki N. Guillain-Barre syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. J Biomed Biotechnol 2011, 2011:829129.
39. Joubert R., Kuchler S., Zanetta J.P., Bladier D., Avellana-Adalid V., Caron M., et al. Immunohistochemical localization of a beta-galactoside-binding lectin in rat central nervous system. I. Light- and electron-microscopical studies on developing cerebral cortex and corpus callosum. Dev Neurosci 1989, 11:397-413.
40. Heilmann S., Hummel T., Margolis F.L., Kasper M., Witt M. Immunohistochemical distribution of galectin-1, galectin-3, and olfactory marker protein in human olfactory epithelium. Histochem Cell Biol 2000, 113:241-245.
41. Matsutani S. Trajectory and terminal distribution of single centrifugal axons from olfactory cortical areas in the rat olfactory bulb. Neuroscience 2010, 169:436-448.
42. Horie H., Kadoya T., Sango K., Hasegawa M. Oxidized galectin-1 is an essential factor for peripheral nerve regeneration. Curr Drug Targets 2005, 6:385-394.
43. Walzel H., Schulz U., Neels P., Brock J. Galectin-1, a natural ligand for the receptor-type protein tyrosine phosphatase CD45. Immunol Lett 1999, 67:193-202.
44. Pace K.E., Hahn H.P., Pang M., Nguyen J.T., Baum L.G. CD7 delivers a pro-apoptotic signal during galectin-1-induced T cell death. J Immunol 2000, 165:2331-2334.
45. Lange F., Brandt B., Tiedge M., Jonas L., Jeschke U., Pohland R., et al. Galectin-1 induced activation of the mitochondrial apoptotic pathway: evidence for a connection between death-receptor and mitochondrial pathways in human Jurkat T lymphocytes. Histochem Cell Biol 2009, 132:211-223.
46. Vespa G.N., Lewis L.A., Kozak K.R., Moran M., Nguyen J.T., Baum L.G., et al. Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation. J Immunol 1999, 162:799-806.
47. Pal Z., Antal P., Millinghoffer A., Hullam G., Paloczi K., Toth S., et al. A novel galectin-1 and interleukin 2 receptor beta haplotype is associated with autoimmune myasthenia gravis. J Neuroimmunol 2010, 229:107-111.
48. Aktas O., Waiczies S., Grieger U., Wendling U., Zschenderlein R., Zipp F. Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. J Neuroimmunol 2001, 114:160-167.
49. Sharma K.G., Radha R., Pao A., Amet N., Baden L., Jordan S.C., et al. Mycophenolic acid and intravenous immunoglobulin exert an additive effect on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transpl Immunol 2010, 23:117-120.
50. Van Beneden K., Coppieters K., Laroy W., De Keyser F., Hoffman I.E., Van den Bosch F., et al. Reversible changes in serum immunoglobulin galactosylation during the immune response and treatment of inflammatory autoimmune arthritis. Ann Rheum Dis 2009, 68:1360-1365.
51. Dong X., Storkus W.J., Salter R.D. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol 1999, 163:5427-5434.
52. Nimmerjahn F., Anthony R.M., Ravetch J.V. Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA 2007, 104:8433-8437.